Abstract 4746
Background
KRAS mutation is a biomarker of exclusion of anti-EGFR agents in patients with mCRC, who have limited options once they progress on oxaliplatin and irinotecan-based regimens. Reo is a naturally occurring, ubiquitous, non-enveloped double stranded RNA virus that selectively replicates in tumor cells harboring KRAS mutations. Reo is synergistic with irinotecan (IRI) in in vitro and in vivo models.
Methods
This was a phase I dose escalation study of FOLFIRI/B and Reo to determine maximum tolerated dose (MTD) and recommended phase two dose (RPTD). Eligible pts were adults with oxaliplatin refractory KRAS-mutant mCRC. Both, IRI (150-180 mg/m2) and Reo (1x1010 TCID50 to 3x1010 TCID50) were escalated. Reo was given intravenously over 1 hour on days 1-5 every 4 weeks (wk). FOLFIRI/B was delivered every 2 wk as per standard protocol. Pharmacokinetics (PK), on study tumor biopsies, and immune response was studied.
Results
36 pts enrolled; 23 females (64%), median age 63 years, FOLFIRI naïve (24) and pre-treated (12). At the highest dose of 180 mg/m2 of IRI, among FOLFIRI pretreated pts, 2 had dose-limiting toxicity (DLT) in cycle 1; one suffered from grade 4 thrombocytopenia, and another developed febrile neutropenia and urosepsis. However, in FOLFIRI naïve patients, none/6 had a DLT. Common (>10%) toxicities included neutropenia, anemia, thrombocytopenia, fatigue, and diarrhea. One patient died of acute renal failure. The MTD was the highest individual dose of FOLFIRI/B (180 mg/m2 IRI) and reovirus (3x1010 TCID50), and is the RPTD. At this dose, 3 of 6 patients (50%) had a PR and the median progression free survival (PFS) and overall survival (OS) were 65.6 wk and > 98.3 wk (as of May 9, 2018), respectively. There was no PK interaction noted. Immunogold staining against viral capsid protein σ demonstrated viral “homing” in the tumor cells. Flow cytometry revealed rapid dendritic cell maturation with subsequent activation of cytotoxic T cells.
Conclusions
The combination of reovirus with FOLFIRI/B is safe, and well tolerated. The PFS and OS is superior to historic data and this combination deserves further exploration.
Clinical trial identification
NCT01274624.
Legal entity responsible for the study
Sanjay Goel.
Funding
Conquer Cancer Foundation and Oncolytics Inc.
Editorial Acknowledgement
Disclosure
S. Goel, A. Ocean: Oncolytics funding to conduct clinical investigations with reovirus. M. Coffey: Employee, Stock owner: Oncolytics Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract